These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12652644)

  • 1. RET and NTRK1 proto-oncogenes in human diseases.
    Alberti L; Carniti C; Miranda C; Roccato E; Pierotti MA
    J Cell Physiol; 2003 May; 195(2):168-86. PubMed ID: 12652644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects.
    Höppener JW; Lips CJ
    Eur J Clin Invest; 1996 Aug; 26(8):613-24. PubMed ID: 8872055
    [No Abstract]   [Full Text] [Related]  

  • 3. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
    J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
    Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features.
    Bongarzone I; Vigneri P; Mariani L; Collini P; Pilotti S; Pierotti MA
    Clin Cancer Res; 1998 Jan; 4(1):223-8. PubMed ID: 9516975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells.
    Pierotti MA; Bongarzone I; Borello MG; Greco A; Pilotti S; Sozzi G
    Genes Chromosomes Cancer; 1996 May; 16(1):1-14. PubMed ID: 9162191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma.
    Musholt TJ; Musholt PB; Khaladj N; Schulz D; Scheumann GF; Klempnauer J
    Surgery; 2000 Dec; 128(6):984-93. PubMed ID: 11114633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
    Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.
    Kusafuka T; Puri P
    Pediatr Surg Int; 1997; 12(1):11-8. PubMed ID: 9035202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
    Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
    Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma.
    Bongarzone I; Fugazzola L; Vigneri P; Mariani L; Mondellini P; Pacini F; Basolo F; Pinchera A; Pilotti S; Pierotti MA
    J Clin Endocrinol Metab; 1996 May; 81(5):2006-9. PubMed ID: 8626874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus.
    Edery P; Pelet A; Mulligan LM; Abel L; Attié T; Dow E; Bonneau D; David A; Flintoff W; Jan D
    J Med Genet; 1994 Aug; 31(8):602-6. PubMed ID: 7815416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor.
    Indo Y
    Clin Auton Res; 2002 May; 12 Suppl 1():I20-32. PubMed ID: 12102460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
    Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
    EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the RET proto-oncogene in Hirschsprung's disease.
    Edery P; Lyonnet S; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékété C; Ponder BA; Munnich A
    Nature; 1994 Jan; 367(6461):378-80. PubMed ID: 8114939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.
    Attié T; Pelet A; Edery P; Eng C; Mulligan LM; Amiel J; Boutrand L; Beldjord C; Nihoul-Fékété C; Munnich A
    Hum Mol Genet; 1995 Aug; 4(8):1381-6. PubMed ID: 7581377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting.
    Peretz H; Luboshitsky R; Baron E; Biton A; Gershoni R; Usher S; Grynberg E; Yakobson E; Graff E; Lapidot M
    Hum Mutat; 1997; 10(2):155-9. PubMed ID: 9259198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
    Frattini M; Ferrario C; Bressan P; Balestra D; De Cecco L; Mondellini P; Bongarzone I; Collini P; Gariboldi M; Pilotti S; Pierotti MA; Greco A
    Oncogene; 2004 Sep; 23(44):7436-40. PubMed ID: 15273715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.